Debiopharm and Cambridge Antibody Technology enter into an exclusive agreement to develop and market SC-1 for gastric carcinomas
17-Oct-2006
SC-1 has completed an academic Phase I/II study in 51 resectable gastric cancer patients. SC-1 has been granted orphan drug designation by the US FDA for gastric cancer.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.